Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.8.3851

Prognostic Significance of HER-2/neu and Survival of Breast Cancer Patients Attending a Specialized Breast Clinic in Kolkata, Eastern India  

Jana, Debarshi (Breast Cancer Research Unit, Breast Service)
Mandal, Syamsundar (Department of Epidemiology and Biostatistics, Chittaranjan National Cancer Institute)
Mukhopadhyay, Madhumita (Department of Pathology, Institute of Post Graduate Medical Education & Research (IPGME&R) and Seth Sukhlal Karnani Memorial Hospital (SSKM))
Mitra, Debabrata (Department of Radiotherapy, Medical College)
Mukhopadhyay, Sunit K. (Department of Veterinary Pathology, West Bengal University of Animal and Fishery Sciences)
Sarkar, Diptendra Kumar (Department of Surgery, Institute of Post Graduate Medical Education & Research (IPGME&R) and Seth Sukhlal Karnani Memorial Hospital (SSKM))
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.8, 2012 , pp. 3851-3855 More about this Journal
Abstract
Introduction: The worldwide incidence of breast cancer has increased rapidly in recent years. The scenario of Eastern India is also showing the same trend. It is necessary to study the utility of HER-2/neu as a prognostic factor in breast cancer survival. However, there have not been detailed studies in this respect with the breast cancer patients of Eastern India. Thus this study was conducted. Materials and Methods: In this hospital-based study 86 breast cancer patients attending a breast clinic of a reputed institute of Eastern India and having invasive ductal carcinomas were observed for a period of 5 years after surgery. Associations between 5 years observed survival and status of ER, PR and HER-2/neu of the patients were critically evaluated. Results: There was statistically significant association between survival pattern for 5 years and the HER-2/neu status (p=0.00001). Better survival was observed for the patients with HER-2/neu negative tumors 67(100%) compared to HER-2/neu positive tumors 7(36.8%). Conclusions: There is strong interaction between survival and HER-2/neu expression of breast cancer patients. Thus the patients with HER-2/neu positive tumors need to be treated aggressively.
Keywords
Breast cancer; prognosis; HER-2/neu; survival; follow-up; Eastern India;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Henson DE, Ries L, Freedman LS, Carriaga M (1991). Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. Cancer, 68, 2142-9.   DOI
2 Laguens G, Coronato S, Di Girolamo W (2006). Biomarkers in breast cancer. CEJMed, 1, 330-47.
3 Nguyen PL, Taghian AG, Katz MS, et al (2009). Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol, 26, 2373-8.
4 Payne SLJ, Bowen RL, Jones JL, Wel CA (2008). Predictive markers in breast cancer - the present. Histopathology, 52, 82-90.
5 Rakkhit R, Broglio K, Peintinger F, et al (2009). Significant increased recurrence rates among breast cancer patients with HER2-positive, T1a,bN0M0 tumors. Cancer Res, 69, 701.
6 Sen U, Sankaranarayanan R, Mandal S, et al (2002). Cancer patterns in eastern India: The first report of the Kolkata Cancer Registry. Int J Cancer, 100, 86-91.   DOI
7 Slamon DJ, Clark GM, Wong SG, et al (1987). Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-82.   DOI   ScienceOn
8 Slamon DJ, Godolphin W, Jones LA, et al (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244, 707-12.   DOI   ScienceOn
9 Taneja P, Maglic D, Kai F, et al (2010). Classical and novel prognostic markers for breast cancer and their clinical significance. Oncology, 4, 15-34.
10 Tovey SM, Brown S, Doughty JC, et al (2009). Poor survival outcomes in HER2-positive breast cancer patients with lowgrade, node-negative tumours. Bri J Cancer, 100, 680-3.   DOI
11 Tsuda H, Hirohashi S, Shimosato Y, et al (1989). Correlation between long term survival in breast cancer patients and amplification of two putative oncogene co-amplification units: hst-1/int-2 and c-erbB-2/ear-1. Cancer Res, 49, 3104-8.
12 Van Belle V, Decock J, Hendrickx W, et al (2011). Short-term Prognostic Index for Breast Cancer: NPI or Lpi. Pathology Research International, 918408, 7 pages.
13 Witton CJ, Reeves JR, Going JJ, Cooke TG (2003). Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol, 200, 290-7.   DOI   ScienceOn
14 Wulfing P, Borchard J, Buerger H, et al (2006). HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res, 12, 1715-20.   DOI
15 Albergaria A, Ricardo S, Milanezi F, et al (2011) . Nottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool? BMC Cancer, 11, 299.   DOI
16 Borg A, Tandon AK, Sigurdsson H, et al (1990). HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res, 50, 4332-7.
17 Carter CL, Allen C, Henson D (1989). Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer, 63, 181-7.   DOI   ScienceOn
18 Chia S, Norris B, Speers C, et al (2008). Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol, 26, 5697-704.   DOI
19 Cooke T, Reeves J, Lanigan A, Stanton P (2001). HER2 as a prognostic and predictive marker for breast cancer. Ann Oncol, 12, 23-8.
20 Dawood S, Broglio K, Buzdar AU, et al (2010). Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an Institutional-Based Review. J Clin Oncol, 28, 92-8.   DOI
21 Ferlay J BF, Pisani P, Parkin DM, (2000). Cancer Incidence, Mortality and Prevalence Worldwide. Globocan, Version 1.0.
22 Ferlay J SH, Bray F, Forman D, Mathers C and Parkin DM (2008). Cancer Incidence and Mortality Worldwide. Globocan, Version 1.2
23 Gonzalez-Angulo AM, Litton JK, Broglio KR, et al (2010). High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, nodenegative tumors 1 cm or smaller. J Clin Oncol, 27, 5700-6.
24 Gullick WJ, Srinivasan R (1998). The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer. Breast Cancer Res Treat, 52, 43-53.   DOI